Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Rhea-AI Summary

Citius Pharmaceuticals (Nasdaq: CTXR) and Citius Oncology (Nasdaq: CTOR) announced management participation in three investor conferences in October 2025. CTXR management will attend LD Micro Main Event XIX (Oct 19-21, 2025) in San Diego and the Think Equity Conference (Oct 30, 2025) in New York. CTOR management will attend the 2025 Maxim Growth Summit (Oct 22-23, 2025) in New York.

Both companies said investors may request 1-on-1 meetings via the event platforms or by contacting the companies' investor relations teams; CTOR noted scheduled meetings with institutional investors and Maxim senior analysts.

LD Micro Main Event XIX, October 19-21, 2025

2025 Maxim Growth Summit, October 22-23, 2025

The Think Equity Conference, October 30, 2025

CRANFORD, N.J., Oct. 17, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and Citius Oncology, Inc. (Nasdaq: CTOR) today announced that management will be participating in three investor conferences in October 2025.

Citius Pharmaceuticals (Nasdaq: CTXR)

Event:	LD Micro Main Event XIX
Date:	October 19-21, 2025
Location:	Hotel Del Coronado, San Diego, California
Event website:	Conference registration
Event:	Think Equity Conference
Date:	October 30, 2025
Location:	Mandarin Oriental, New York
Event website:	Conference registration

Interested parties may schedule 1-on-1 meetings with Citius management by registering through the event platform or contacting the Company's investor relations team.

Citius Oncology (Nasdaq: CTOR)

Event:	2025 Maxim Growth Summit
Date:	October 22-23, 2025
Location:	The Hard Rock Hotel, New York
Event website:	Conference Registration

Citius Oncology will be meeting with institutional investors in a one-on-one format, and senior Maxim analysts during the event.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok^®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 79% of Citius Oncology. For more information, please visit www.citiuspharma.com.

About Citius Oncology, Inc.

Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com

Investor Contact:

Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-and-citius-oncology-to-participate-in-upcoming-october-2025-conferences-302586084.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

When will Citius Pharmaceuticals (CTXR) present at LD Micro Main Event XIX?

CTXR management will be at LD Micro Main Event XIX on October 19-21, 2025 at Hotel Del Coronado in San Diego.

What date will Citius Pharmaceuticals (CTXR) attend the Think Equity Conference?

CTXR management will attend the Think Equity Conference on October 30, 2025 at the Mandarin Oriental in New York.

When and where will Citius Oncology (CTOR) participate in the Maxim Growth Summit?

CTOR management will be at the 2025 Maxim Growth Summit on October 22-23, 2025 at The Hard Rock Hotel in New York.

How can investors schedule 1-on-1 meetings with CTXR or CTOR at the October 2025 conferences?

Investors may schedule 1-on-1 meetings by registering through each event's platform or contacting the companies' investor relations teams.

Will Citius Oncology (CTOR) meet with analysts at the Maxim Growth Summit?

Yes, CTOR indicated it will meet with institutional investors in one-on-one meetings and with senior Maxim analysts during the event.

Which Nasdaq ticker symbols correspond to the companies attending the October 2025 conferences?

Citius Pharmaceuticals trades under CTXR and Citius Oncology trades under CTOR on Nasdaq.